Avalo Therapeutics (AVTX) Current Deferred Revenue (2022 - 2023)
Avalo Therapeutics' Current Deferred Revenue was $111,000 in Q1 2023, up 26.1% from the prior quarter.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Current Deferred Revenue (2022 - 2023) Analysis & Trends
At the end of FY2022, Current Deferred Revenue at Avalo Therapeutics came in at $88,000.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn |
| 10 | Avalo Therapeutics | 533.82 Mn | -158.40 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 111,000.00 |
| Dec 31, 2022 | 88,000.00 |
| Sep 30, 2022 | 442,000.00 |
API Access
Avalo Therapeutics Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=AVTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "AVTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=AVTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();